|Ascendis Pharma A/S, of Copenhagen||Transcon PTH||Parathyroid hormone prodrug||Hypoparathyroidism||European Commission granted orphan designation|
|Astrazeneca plc, of Dublin||AZD-1222||Vaccine||COVID-19||FDA authorized restart of clinical trials|
|Evgen Pharma plc, of Cheshire, U.K.||SFX-01||Up-regulates Nrf2 pathway||Acute respiratory distress syndrome in patients with suspected COVID-19||All necessary regulatory approvals have been received for the phase II/III STAR trial and recruitment is expected to commence around the end of the month|
|Kezar Life Sciences Inc., of South San Francisco||KZR-616||Immunoproteasome inhibitor||Polymyositis and dermatomyositis||FDA granted orphan drug designations for both indications|
For more information about individual companies and/or products, see Cortellis.